Smith-Magenis Syndrome (SMS)
·MeSH: Smith-Magenis Syndrome
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| hetlioz | Vanda Pharmaceuticals Inc. (VNDA) |
Frequently asked questions
How many drugs are in development for Smith-Magenis Syndrome (SMS)?
BioSniper tracks 1 drug in development for Smith-Magenis Syndrome (SMS) across 1 company.
How many clinical trials target Smith-Magenis Syndrome (SMS)?
There are 1 clinical trial targeting Smith-Magenis Syndrome (SMS) tracked by BioSniper.
What is the prevalence of Smith-Magenis Syndrome (SMS)?
The estimated prevalence of Smith-Magenis Syndrome (SMS) is approximately 5.0 per 100,000 population.
Deep-dive into Smith-Magenis Syndrome (SMS)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis